The significant miss in both earnings per share and sales compared to analyst estimates, coupled with the year-over-year decline in these metrics, suggests a negative short-term impact on Co-Diagnostics' stock price. The magnitude of the miss, especially the sales missing estimates by 84.66%, indicates underlying challenges that could affect investor confidence and stock performance in the near term.